Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases
Rupert Bartsch(Universitätszahnklinik Wien), Matthias Preusser(Medical University of Vienna), Thorsten Fuereder(Medical University of Vienna), Sophie Roider‐Schur, Leopold Oehler, Birgit Gruenberger(Fachhochschule Wiener Neustadt), Christian F. Singer(Comprehensive Cancer Center Vienna), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Luzia Berchtold(Statistics Austria), Anna S. Berghoff(Medical University of Vienna), Heidrun Forstner(Medical University of Vienna), Julia Furtner(Medical University of Vienna), Marie‐Bernadette Aretin(Vienna General Hospital), Christoph Minichsdorfer(Medical University of Vienna), Angelika M. Starzer(Medical University of Vienna), Elisabeth Bergen(Medical University of Vienna), Karin Dieckmann(University of Vienna), Maximilian Marhold(Medical University of Vienna), Georg Widhalm(Medical University of Vienna), Helmuth Haslacher(Medical University of Vienna), Georg Pfeiler(Medical University of Vienna), Maximilian J. Mair(Medical University of Vienna), Beate Rottenmanner(Medical University of Vienna), Thomas Szekeres(Medical University of Vienna), Ansgar Weltermann, Aysegül Ilhan‐Mutlu(Medical University of Vienna)
Cited by 60
Related Papers
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
High Plasma Levels of Factor VIII and the Risk of Recurrent Venous Thromboembolism
|New England Journal of Medicine|2000|765